Salute e Benessere

New MS patient companion App, Ekiva-MS, launched by Dawn Health to empower…

The experience and symptoms for PlwMS is very dependent on the individual patient and presents in unpredictable ways for every patient, leading to high levels of uncertainty and concern between HCP interactions. As a lifelong condition that affects the body's nervous system, MS impacts every person differently, with severity or even existence of different symptoms and quality of life impacts varying significantly across the patient population. This leads to treatment of MS being more challenging…

TATAA Biocenter promotes Sofia Adolfsson to Scientific Officer and Head of…

"Sofia has been an invaluable member of our team since she joined us in 2021," said Mathias Hallin, CEO of TATAA Biocenter. "We are thrilled to promote her to this new role and are confident that she will continue to drive innovation and deliver exceptional results for our company and the biopharmaceutical industry as a whole." "Sofia has been an invaluable member of our team since she joined us in 2021," saidMathias Hallin, CEO of TATAA Biocenter. "We are…

FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology…

A second Numares assay is expected to gain FDA 510(k) clearance later this year, the AXINON® GFR(NMR) kidney function assay. A second Numares assay is expected to gain FDA 510(k) clearance later this year, theAXINON ® GFR(NMR) kidney function assay. Numares is a health care diagnostics company that develops improved diagnostic testing for conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. From a single blood sample, Numares quantifies...

First clinical study results of psilocybin treatment in anorexia nervosa…

COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa Nature Medicine that demonstrates the potential for COMP360 psilocybin treatment in anorexia nervosa. The investigator-initiated open-label study was conducted by Drs. Walter Kaye and Stephanie Knatz Peck at the University of California San Diego School of Medicine and is believed to be the first clinical research study to report the effects of psilocybin treatment in...

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its…

Oral Presentation Session: Pathways and mechanisms governing the pathogenesis of asthma and chronic obstructive pulmonary disease Oral Presentation Session: Pathways and mechanisms governing the pathogenesis of asthma and chronic obstructive pulmonary disease Monday September 11, 2023 Time: 9:30 am CET Location:Allianz MiCo,Milan Room: Brown 1+2 ( https://www.ersnet.org/wp-content/uploads/2023/07/PROGRAMME-2023-0507.pdf ) "We are very excited to have the...

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief…

Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics. Our lead program is a first-in-class product that has shown exceptional performance across a range of preclinical efficacy and safety testing. Beyond our lead program, we are leveraging our platform to build a pipeline of high-value ADC products. I am honored and excited to lead this team as we…

Liverpool Women's is First to Complete Modern EPR Milestone

"Liverpool Women's Hospital has undertaken a significant programme of work replacing the Trust's legacy Patient Administration System (PAS) with a modern electronic patient records (EPR) solution. The size of the task was increased due to the age of the system as it had originally been implemented in 1996," said Matt Connor, Chief Information Officer for Liverpool Women's NHS Foundation Trust. "Liverpool Women's Hospital has undertaken a significant programme of work replacing the…

FutureMeds Leads the Way: The First European DCT Site Network Driving Momentum…

Radoslaw Janiak, CEO at FutureMeds, said, "We're excited to drive meaningful momentum and results for our clients and patients. Speeding up the DCT adaptation process across the clinical trial industry in Europe can boost pharmaceutical R&D productivity, support and influence commercialisation strategies, and significantly enhance the patient experience, engagement and outcomes." Radoslaw Janiak, CEO at FutureMeds,said,"We're excited to drive meaningful momentum and results…

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7…

Diabetic Retinopathy (DR) affects 30% of diabetic patients and is one of the leading causes of blindness among working age adults. Age-Related Macular Degeneration (AMD) is another prominent cause of vision loss, particularly for individuals aged 60 years and older. Diabetic Retinopathy (DR) affects 30% of diabetic patients and is one of the leading causes of blindness among working age adults. Age-Related Macular Degeneration (AMD) is another prominent cause of vision loss, particularly for...

Final Results

DXS INTERNATIONAL PLC(AQSE: DXSP)ANNUAL RESULTS for the year ended 30 April 2023 The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2023. Financial highlights:Revenue increased by 3% to £3,391,219 (2022: £3,285,050). Core recurring revenue model continues to be resilient...

Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License…

Total Potential Development and Commercial Milestones of $32M plus Royalties Leuven, BELGIUM, Boston, MA, US – July 25 , 2023 – 8:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it received approximately $400,000 in an upfront payment following the exercise of an option by a third party to...

Idorsia announces financial results for the first half 2023 – adapting the…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25 , 2023Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2023. Business highlights Transaction withSosei Heptares:Idorsia sells its Asia Pacific (ex-China) operations – including selected license rights to products – for a total consideration of CHF 400 million. Cost reduction initiativewith the target of a reduction in cash-burn at headquarters by...

Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts…

Key Takeaways from the Cutaneous Melanoma Market Report Key Takeaways from the Cutaneous Melanoma Market Report Discover which therapies are expected to grab the major cutaneous melanoma market share @Cutaneous Melanoma Market Report Cutaneous Melanoma Overview Cutaneous melanoma is a type of skin cancer that develops in the melanocytes, the cells responsible for producing melanin, the pigment that gives color to the skin. It is the most aggressive form of skin cancer and...

EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023

ACCELERATION OF STRATEGIC DEPLOYMENTIN THE FIRST HALF OF 2023Strong growth in half-year core business revenues, up 37%Successful deployment of the Group's strategy: Share of proprietary products up, at 30% of revenuesContinued internationalization, with 35% of revenues now generated outside of FranceAcquisition of DID in Italy effective as of July 1 st, 2023Paris, July 24 , 2023– 5:45 pmEurobio Scientific(FR0013240934, ALERS, PEA-PME eligible), a...

Home Office Furniture Market Size, Growth Potential And Forecast To 2032 - By…

The global home office furniture market is highly fragmented, with a large number of small players in the market.HNI Corporationwas the largest home office furniture manufacturer with 2.7% share of the market, followed by Ashley Furniture Industries Inc., Steelcase Inc., MillerKnoll, Inc., KOKUYO Furniture, Haworth Inc., OKAMURA Corporation, Godrej & Boyce Mfg. Co. Ltd., Ethan Allen Interiors Inc. and Bernhardt Furniture Company Inc. Learn More On The Home Office...

Sexual Wellness Market Size to Reach USD 110.33 Billion, Globally, by 2030 at…

Sexual Wellness Market: Overview Sexual Wellness Market: Overview Sexual health is a fundamental human need. It is essential for the health and well-being of couples, individuals, families, and society as a whole. It is necessary for the growth of communities and the advancement of nations. Sexual health must be regarded positively. The concept of sexual well-being should be regarded with reverence. The official definition of sexual wellness has contributed to a broader comprehension of...

Medical Aesthetics Market size worth $ 27.55 Billion, Globally, by 2028 at 10.6%…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=23849 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=23849 Browse in-depth TOCon" Medical Aesthetics Market " 202 - Pages 126 – Tables 37 – Figures Market for Medical Aesthetics: Growing Demand and New Opportunities Fuel Market Growth The demand for aesthetic operations is on the rise due to improvements in medical technology and rising...

AvenCell Therapeutics Announces EMA Approval of Clinical Trial Application (CTA)…

"We are excited to build on the early success and promising activity and safety of our ongoing switchable autologous clinical program in AML (AVC-101) by now including what we believe is the most scientifically-compelling allogeneic technology in the industry," said Andrew Schiermeier, AvenCell's President & CEO. "With the application of both platform technologies, we are the first company in this space to completely separate the manufacture of cells from the ultimate patients…

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 24July 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.Under the...

Curia expands biologics capabilities with access to Touchlight's doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™) “Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities,” said Christopher Conway, President of R&D, Curia. “With the addition of enzymatic DNA through our partnership with Touchlight, our customers will have a critical advantage in terms of scalability and speed to market.”Touchlight's dbDNA is a...

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule…

This research, published in Nature on June, 21st 2023 and titled "Structure and mechanism of action of the RAD51BCD-XRCC2 tumor suppressor complex" was led by renowned cancer researchers Stephen West and Simon Boulton, from the Francis Crick Institute, London, UK. This research, published inNatureon June, 21st 2023 and titled"Structure and mechanism of action of the RAD51BCD-XRCC2 tumor suppressor complex"was led by renowned cancer researchers Stephen WestandSimon Boulton…

MitoSense Officially Joins CAMP as Partner for Advanced Therapy Medicinal…

Van Hipp, Chairman of MitoSense, commented: "We are thrilled to partner with CAMP, an esteemed organization dedicated to the development of ATMPs. This partnership allows us to combine our unique MOT™ technology with CAMP's expertise, accelerating the development of life-changing therapies for patients suffering from neurodegenerative diseases." Van Hipp, Chairman of MitoSense, commented: "We are thrilled to partner with CAMP, an esteemed organization dedicated to the development…

ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of…

As part of the agreement, SpectronRx will be responsible for manufacturing a critical component of ARTBIO's proprietary AlphaDirect™ technology. AlphaDirect™ is a first-of-its-kind system that delivers highly pure Pb212 from widely available raw materials. The multi-year agreement covers an initial technology transfer and development phase, followed by qualification and release of the technical components. As part of the agreement, SpectronRx will be responsible for manufacturing a critical...

SomaLogic partners with Dante Genomics to enhance clinical and research adoption…

"Over the past seven years, Dante has been intensely focused on enhancing the clinical utility of the genome, and in partnering with SomaLogic, we will now work together to enhance the research and discovery capabilities of the proteome," said Andrea Riposati, Co-founder and CEO of Dante Genomics. "By combining proteomics and genomics, we will develop clinical insights and actionable results. We are excited for the future of multiomics, where partnerships like this will mean…

Altri Comunicati